PKNOX2 expression and regulation in the bone marrow mesenchymal stem cells of Fanconi anemia patients and healthy donors

Ilgin Cagnan1, Erdal Cosgun2, Ozlen Konu3, Duygu Uckan1,4, Aysen Gunel-Ozcan1*

1Department of Stem Cell Sciences, Graduate School of Health Sciences, Center for Stem Cell Research and Development, Hacettepe University, Ankara, Turkey.
2Department of Biostatistics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
3Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey.
4Department of Pediatrics, Division of Bone Marrow Transplantation Unit, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

*Corresponding author: Assoc. Prof. Aysen Gunel-Ozcan, M.D., Ph.D.

Hacettepe University Department of Stem Cell Sciences,
Center for Stem Cell Research and Development,
06100 Sihhiye, Ankara, Turkey
Telephone: +90 312 305 2821
E-mail: agozcan@hacettepe.edu.tr

Current address: Blood Bank, Burhan Nalbantoglu State Hospital, Nicosia, North Cyprus
Current address: Microsoft Research, 14820 NE 36th Street, Building 99, Redmond, Washington, 98052, USA

Email Addresses of Authors: Ilgin Cagnan: icagnan@hotmail.com (https://orcid.org/0000-0003-1255-2788); Erdal Cosgun: ercosgun@microsoft.com (https://orcid.org/0000-0002-1068-6523); Ozlen Konu: konu@fen.bilkent.edu.tr; Duygu Uckan: duckan@hacettepe.edu.tr
Acknowledgements

This study was supported by The Scientific and Technological Research Council of Turkey (TUBITAK; project no: 110S021 in conjunction with EU COST Action BM0805 designated as ‘HOX and TALE transcription factors in Development and Disease’ and TUBITAK project no: 214Z033). The data in this study is a part of Ilgin Cagnan’s Ph.D. thesis.
Summary

**Background:** HOX and TALE transcription factors are important regulators of development and homeostasis in determining cellular identity. Deregulation of this process may drive cancer progression. The aim of this study was to investigate the expression of these transcription factors in the bone marrow derived mesenchymal stem cells (BM-MSCs) of Fanconi anemia (FA) patients, which is a cancer-predisposing disease.

**Methods and Results:** Expression levels of HOX and TALE genes in BM-MSCs were obtained from FA patients and healthy donors by RT-qPCR and highly conserved expression levels were observed between patient and donor cells, except *PKNOX2*, which is a member of TALE class. *PKNOX2* was significantly downregulated in FA cells compared to donors (*P* < 0.05). *PKNOX2* expression levels did not change with diepoxybutane (DEB), a DNA crosslinking agent, in either donor or FA cells except one patient’s with a truncation mutation of *FANCA*. A difference of *PKNOX2* protein level was not obtained between FA patient and donor BM-MSCs by western blot analysis. When human TGF-β1 (rTGF-β1) recombinant protein was provided to the cultures, *PKNOX2* as well as *TGF-β1* expression increased both in FA and donor BM-MSCs in a dose dependent manner. 5 ng/mL rTGF-β stimulation had more dominant effect on the gene expression of donor BM-MSCs compared to FA cells.

**Conclusion:** Decreased *PKNOX2* expression in FA BM-MSCs may provide new insights into the molecular pathophysiology of the disease and TGF-β1 levels of the microenvironment may be the cause of *PKNOX2* downregulation.

**Keywords:** PKNOX2; HOX genes; TALE class; TGF-β1; Fanconi anemia; bone marrow mesenchymal stem cells
Introduction

Cellular identity is established during developmental process when cells progressively gain specific lineage properties through the guidance of transcriptional networks. Organ-specifically expressed HOX genes encode ‘master regulatory’ homeodomain transcription factors that function in specifying anterior-posterior patterning and establish regional identity during embryonic development [1-3]. In mammals, HOX genes are found in four clusters, designated as A, B, C and D, which are located on different chromosomes. DNA binding specificity of HOX proteins is increased through protein-protein interactions with the members of three-amino-acid loop extension (TALE) class homeodomain proteins, known as Meis (MEIS1, MEIS2, MEIS3), Pknox (PKNOX1, PKNOX2) and Pbx (PBX1, PBX2, PBX3, PBX4) gene families [4, 5]. Besides their role in embryonic development, TALE members act as oncogenes (e.g. MEIS1) and tumor suppressors (e.g. PKNOX1), as well as function in DNA repair and maintain genomic stability (e.g. PKNOX1) [6, 7].

During adult life, tightly regulated HOX expression pattern continues to provide a “biological fingerprint” for different cell types [8-10]. Loss of cellular identity through alterations in HOX pathway is one of the driving mechanisms of cancer development such as solid tumors and leukemia [11, 12]. Genomic instability in patients (e.g. Fanconi anemia, Wemer syndrome, Bloom syndrome and Ataxia telangiectasia) with defective DNA damage repair pathway (i.e. direct reversal, homologous recombination, non-homologous end joining, mismatch repair, nucleotide excision repair and base excision repair) is also a contributor of cancer progression [13, 14]. We hypothesize that HOX code may change in the diseases with defective DNA repair pathway and predisposition to cancer. To test this hypothesis, we profiled HOX and TALE gene expression in Fanconi anemia (FA) patients, which is a rare inherited disorder with an estimated incidence of 1 in 160,000-360,000 live births [15, 16]. FA patients are characterized with congenital malformations, predisposition to leukemia and
solid organ cancers and bone marrow (BM) failure [15]. Mutations in twenty-two different
genes, which encode FA complementation group (FANC) proteins and are involved in DNA
repair pathway, are responsible for the disease [15, 17]. Moreover, patient cells display
hypersensitivity to DNA interstrand crosslinking agents, such as diepoxybutane (DEB),
which lead to DNA damage through high levels of chromosomal breaks [18]. The molecular
basis of the FA pathophysiology has not been completely elucidated. A study by Zhang et al
(2016) shows hyperactive transforming growth factor-beta (TGF-β) signaling as a cause of
BM failure in the patients [19]. Members of TGF-β signaling pathway is reported to interact
with HOX genes [20-23], thus deregulation of TGF-β signaling in FA patients may disturb
HOX and TALE gene expression as well. Therefore, we also investigated the degree of
association between TGF-β and modulation of PKNOX2, which we found out differentially
expressed in FA.

Materials and Methods

Bone Marrow Mesenchymal Stem Cells from FA Patients and Donors

Bone marrow mesenchymal stem cells (BM-MSCs) obtained from FA patients (HUSCS-FA1
-12; n = 12) and donors (HUSCS-D1-16; n = 16) were used. Cells were maintained in
DMF10 medium, which contained 100 U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-
glutamine (Biochrom AG, Germany) and 10% heat-inactivated fetal bovine serum (GIBCO, UK) in a mixture of 60% Dulbecco’s modified Eagle’s medium-low glucose (GIBCO) and
40% MCDB-201 medium (Sigma-Aldrich, USA). Passage 3 BM-MSCs were used in the
following experiments. Characterization of BM-MSCs was published previously [24, 25].
Informed consent was obtained from FA patients and donors enrolled in this study. This
study was approved by the Local Ethical Committee (Number 14, 24/08/2009) and Hacettepe
University Non-interventional Clinical Research Ethics Board (GO 14/403-12, 23/07/2014).
Details of RNA isolation, cDNA synthesis and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) analysis were outlined previously [24, 26]. cDNAs were synthesized from 260 ng RNA samples per 20 µl. Expression of 39 HOX and 8 TALE genes were analyzed using RealTime ready Assay (Roche, USA). Target gene expression was normalized against house keeping gene, \textit{ACTB}. Relative gene expression was determined by \(\Delta\text{Ct}\) method, calculated by log transformation of \(2^{-\Delta\text{Ct}}\). To enhance the efficiency of statistical analyses, missing \(\Delta\text{Ct}\) values were imputed by Multivariate Imputation by Chained Equations (MICE) in R Project for Statistical Computing [27]. MICE method involved assigning a default value for each missing entry. Each column was then updated by appropriate regression or classification algorithm and \textit{Number of Iterations} parameter showed number of times the updates were repeated [28, 29].

**Western blot Analysis**

The differentially expressed gene obtained by RT-qPCR profiling was also determined at protein level. Total protein lysates from BM-MSCs were prepared using Pierce\textsuperscript{®} RIPA Buffer (Thermo Scientific, USA) containing 1X protease inhibitor cocktail (Sigma-Aldrich). Protein lysates in Laemmli Buffer (Bio-Rad, USA) containing 355 mM 2-mercaptoethanol (Bio-Rad) were denatured by boiling for 5 minutes, and then separated by SDS-PAGE, using 10% TGX Stain-Free FastCast Acrylamide kit (Bio-Rad) following manufacturer’s protocol. Proteins were transferred to a PVDF membrane by Trans-Blot\textsuperscript{®} Turbo\textsuperscript{TM} Transfer System (7 minutes, 2.5 A and \(\leq\) 25 V; Bio-Rad). Membranes were blocked in TBS containing 0.1% Tween 20 (TBS-T; Bio-Rad) and 5% dry milk (Bio-Rad) for 1 hour at room temperature, followed by incubation with 1:100 diluted mouse-anti-PKNOX2 primary antibody (Santa Cruz Biotechnology, USA, Cat# sc-101857) overnight at 4 °C. Membranes were washed with TBS-T, followed by incubation with HRP-goat-anti-mouse secondary antibody (1:2000...
dilution; Abclonal, USA) for 1 hour at room temperature. Peroxidase activity was measured using Clarity Western ECL Substrate kit (Bio-Rad), following manufacturer’s protocol and images were obtained by Kodak Gel Logic 1500 Imaging System (Thermo Fisher Scientific). Membranes were washed, re-blocked, and re-blotted with 1:2500 diluted rabbit-anti-β-ACTIN (Cell Signaling Technology, USA, Cat# 8457). Subsequent steps were same as described above, but HRP-goat-anti-rabbit secondary antibody (Abclonal) was used. PKNOX2 protein levels were compared between samples according to signal intensity of PKNOX2 protein bands normalized to loading control β-ACTIN. Densitometry analyses were performed by evaluating band intensity of mean grey value using ImageJ software [30, 31].

DEB Treatment of BM-MSCs

FA cells show sensitivity to DNA interstrand crosslinking agents, such as DEB. Once treated with DEB, patient cells acquire chromosome breaks and undergo cell cycle arrest as well as genomic instability [18]. BM-MSCs derived from FA patients (n = 6) and donors (n = 3) were treated with 0.1 μg/mL DEB (Sigma-Aldrich) in DMF10 medium, as outlined previously [25]. Untreated cells cultured in DMF10 medium were used as control. cDNAs synthesized from 260 ng RNA samples were used in RT-qPCR analysis to determine the effect of DEB treatment on PKNOX2 relative expression. When Ct value was not acquired, ΔCt was accepted as -25.

Culture of BM-MSCs with Recombinant Human TGF-β1 protein

BM-MSCs from FA patients or donor were plated into 6-well plates and kept in a 5% CO2 incubator at 37 °C for 24 hours. Cells were then induced with 0.1 or 5 ng/mL of recombinant human TGF-β1 protein (rTGF-β1; BioLegend, USA) containing DMF10 medium for 24 hours. Uninduced cells maintained in DMF10 medium were included as controls. The effect of rTGF-β1 treatment on PKNOX2, MEIS1, PBX1 and TGF-β1 expression in BM-MSCs
from FA patients (n = 5) and donors (n = 5) was determined. Following induction, BM-MSCs were trypsinized in 0.25% trypsin (Invitrogen, UK) containing 1 mM EDTA (Invitrogen) and washed with PBS (Applichem, Germany), followed by RNA isolation and cDNAs synthesis (i.e. 130 ng RNA was used), according to above protocol. Fold change (FC) in gene expression between induced and control cells were calculated by applying a log transformation to $2^{-\Delta\Delta CT}$ [32]. The effect of rTGF-β1 induction on PKNOX2 protein level of BM-MSCs from FA patients (n = 3) and donors (n = 3) was determined using western blot analysis, following the above protocol.

Statistical Analysis

Statistical analyses were performed using IBM SPSS Statistic software, V24 and graphics were constructed using GraphPad Prism 7, unless stated otherwise. To compare two independent groups, Student’s t-test or Mann Whitney U (MWU) test was performed and $P$-value less than 0.05 was considered as statistically significant. To compare three dependent groups, Friedman’s 2-way ANOVA by ranks test was used and if asymptotic $P$-value was less than 0.05, pairwise test with Bonferroni correction was applied to test the significance within two groups (i.e. adjusted $P < 0.05$). Heat-map (clustering method: single linkage; distance method: Euclidian), as well as scatter-plot showing differentially expressed genes between groups was constructed using Exiqon GenEx qPCR analysis software. Spearman correlation analysis was performed on GraphPad Prism 7 software and was expressed as correlation coefficient (r).

Results

HOX and TALE Profile of BM-MSCs

HOX and TALE genes had a conserved expression between FA patient and donor BM-MSCs. Cells had no $HOXB1$ expression, whereas they had low and inconsistent expression of $HOXB13$, $HOXC12$, $HOXD10$, $HOXD11$, $HOXD12$ and $HOXD13$ (Online Resource 1), thus
these genes were excluded from imputation and further analysis. HOX and TALE gene expression was grouped into six clusters (Fig. 1a). The first cluster included HOXA13, HOXB4, HOXB8, HOXD3, HOXD4, HOXD9 and PBX4 ($\Delta C_{\text{tmin}} = -18.79$, $\Delta C_{\text{tmax}} = -11.91$).

The second cluster was consisted of HOXA1, HOXA2, HOXA3, HOXA4, HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, HOXA11, HOXB2, HOXB3, HOXB5, HOXB6, HOXB7, HOXC4, HOXC5, HOXC6, HOXC8, HOXC9, HOXC11, HOXD8, MEIS1, MEIS2, PBX1, PBX2, PBX3, PKNOX1 and PKNOX2 ($\Delta C_{\text{tmin}} = -17.59$, $\Delta C_{\text{tmax}} = -5.45$). HOXD1 ($\Delta C_{\text{tmin}} = -18.05$, $\Delta C_{\text{tmax}} = -12.73$), HOXB9 ($\Delta C_{\text{tmin}} = -18.74$, $\Delta C_{\text{tmax}} = -11.25$), HOXC13 ($\Delta C_{\text{tmin}} = -18.97$, $\Delta C_{\text{tmax}} = -13.90$) or HOXC10 ($\Delta C_{\text{tmin}} = -7.10$, $\Delta C_{\text{tmax}} = -4.03$) were clustered alone (Fig. 1a).

Additionally, HOXC10 had the highest relative expression level in all BM-MSCs (Fig. 1a).

Correlation analysis revealed that gene expression was highly associated ($r = 0.9861$, $P < 0.0001$) between FA patients and donors, while PKNOX2 and HOXC13 were differentially expressed between groups (Fig. 1b).

Statistical analysis revealed that expression of HOX (Fig. 2a-d) genes, as well as MEIS1, MEIS2, PBX1, PBX2, PBX3, PBX4 and PKNOX1 (Fig. 2e) were not significantly ($P > 0.05$) different between groups. However, PKNOX2 expression of FA patients (-15.19 ± 1.49) was significantly lower than ($P < 0.05$) the expression of donors (-13.24 ± 1.37; Fig. 2e). DEB treatment had no effect on PKNOX2 relative expression levels of FA patients and donors, except one patient’s BM-MSCs (HUSCS-FA04) which lost the expression of PKNOX2 ($\Delta C_{t} = -25$) by DEB treatment (Fig. 2f). Western blot analysis revealed that BM-MSCs probably had more than one PKNOX2 isoform (Fig. 3a). When variants corresponding to 70 kDa (i.e. large) and 52 kDa (i.e. small) were quantified, cells had higher levels of large variant compared to small one (Fig. 3b). Additionally, level of large and small PKNOX2 isoforms did not differ ($P > 0.05$) between FA patient (1.21 ± 0.28 and 0.30 ± 0.07, respectively) and donor cells (1.19 ± 0.33 and 0.24 ± 0.06, respectively; Fig. 3b).
Effect of rTGF-β1 Induction on PKNOX2 and TGF-β1 Levels

For each experimental condition (i.e. control, 0.1 or 5 ng/mL rTGF-β1 protein), fold change in gene expressions of both FA and donor BM-MSCs were upregulated as the dose of rTGF-β1 increased (Fig. 4a-b). When compared to their corresponding uninduced controls, increase in PKNOX2 expression was significant in both FA (Log$_2$ FC = 2.37 ± 0.84) and donor (Log$_2$ FC = 3.09 ± 0.58) BM-MSCs induced with 5 ng/mL rTGF-β1 protein (adjusted $P < 0.05$; Fig. 4a). The same dose also provided a significant increase in TGF-β1 expression of the donor BM-MSCs (Log$_2$ FC = 1.10 ± 0.16); adjusted $P < 0.05$; Fig. 4b), but not of the FA BM-MSCs. Fold change differences in either PKNOX2 (Fig. 4a) or TGF-β1 (Fig. 4b) were not significant when FA patients compared to donors ($P > 0.05$). rTGF-β1 treatment of BM-MSCs did not alter MEIS1 (Fig. 4c) or PBX1 (Fig. 4d) expression levels ($P > 0.05$).

Level of PKNOX2 protein was determined prior to and after induction with 0.1 and 5 ng/mL rTGF-β1 protein (Fig. 5). All samples had higher level of large variant (70 kDa) compared to small isoform (52 kDa; Fig. 5a). PKNOX2 protein level remained unchanged ($P > 0.05$) between FA and donor BM-MSCs at any experimental condition (Fig. 5b). Additionally, PKNOX2 protein level within either FA patients or donors did not change significantly ($P > 0.05$) upon induction (Fig. 5b).

Discussion

The molecular signature of HOX expression is organ-specific [8, 9]. Changes in HOX pathway may result in alterations in the cellular identity and trigger cancer progression [11, 12]. One of the aims of this study was to assess, whether HOX and TALE gene expression pattern changed in diseases predisposed to cancer, like FA. At the third passage, FA BM-MSCs had comparable HOX gene expression levels with donor cells, but HOX13 expression was relatively lower in patients. In conjunction with other studies, we also found that most HOX genes, except HOX1, HOX13, HOX12, HOX10, HOX11, HOX12
and HOXD13, were actively expressed by BM-MSCs [33, 34]. Expression of HOXA9, HOXA10, HOXC6, HOXC8, HOXC10 and HOXD8 in BM-MSCs is known to be higher than other HOX genes, as also observed in our study [33, 34]. Liedtke and co-authors (2010) have reported that HOXA3, HOXA11, HOXA13, HOXB2, HOXB3, HOXB8, HOXB9, HOXC11, HOXC13 and HOXD1 expression was absent in BM-MSCs [33], but we observed that they were expressed at low to intermediate level. 

In our study, BM-MSCs also actively expressed members of TALE gene class. Intriguingly, BM-MSCs derived from FA patients had significantly lower PKNOX2 expression compared to donors. We analyzed two different GEO datasets (GSE61853 and GSE87806) containing gene expression profile of bone marrow mesenchymal stromal cells from other bone marrow diseases (myelodysplastic syndrome –MDS-, polycythemia vera –PV-, and essential thrombocytemia –ET-, chronic myeloid leukemia –CML-) to test whether PKNOX2 expression level changed under other disease states. We found that PKNOX2 expression of mesenchymal stromal cells from MDS, PV, ET or CML patients did not significantly differ from controls (adjusted $P > 0.05$; Online Resource 2) [35, 36]. According to the results of these datasets, decrease in PKNOX2 expression is restricted to FA patients. Additionally, It would be intriguing to compare, whether PKNOX2 expression changes upon cell passaging. 

Due to their low frequency (0.001-0.01% of nucleated cells) in the bone marrow [37], BM-MSCs have to be expanded in-vitro, which prevents the use of fresh explants. However, passaging BM-MSCs for a long-term trigger senescence and affect their proliferative capacity [38, 39]. Also, FA BM-MSCs have defects in their proliferation capacity and undergo senescence in-vitro [40]. Therefore, the passage number is one of the limitations of this study. 

Unlike its mRNA level, PKNOX2 protein level did not change between FA patients and healthy donors. Protein and mRNA levels of a gene may not always correlate with each other due to post-transcriptional modifications or half-lives of proteins [41]. Herein, we obtained
expression of two different PKNOX2 isoforms in BM-MSCs, corresponding to 70 and 52 kDa. On the SDS-PAGE gel, smaller variant had the expected molecular weight of PKNOX2, while the molecular weight of large isoform corresponded to the in-vitro synthesized protein by Fognani et al (2002) [42]. Similar to our findings, NIH3T3 mouse embryo fibroblast cell line is shown to have variants of PKNOX2 protein [43]. Clear function of PKNOX2 is not well understood apart from its role in regulation of transcription through sequence-specific DNA binding and actin filament/monomer binding. Furthermore, Pknox2 overexpression in mice limb bud mesenchyme results in hypoplastic radius and ulna, which are common defects observed in FA patients [44]. PKNOX2 has a high structural similarity to its paralogous gene PKNOXI, which is known to function as a tumor suppressor gene with roles in DNA repair and maintenance of genomic stability [6, 7, 42]. This might implicate that PKNOX2 could also be a potential player in the DNA repair of FA stromal environment. Indeed, a whole genome RNA interference (RNAi) study showed that PKNOX2 silencing increased cellular sensitivity to ionizing radiation [45]. However, our study showed that DEB treatment of BM-MSCs did not change the expression of PKNOX2 in either donor or FA patients, except one that possessed a novel deletion of exon 1-2 in FANCA gene, reported in our previous study [25]. PKNOX2 expression is lost by DEB treatment in that patient’s BM-MSCs. Truncation mutation of that patient is probable to be more deleterious and can increase cellular sensitivity to cross linking agents such as DEB by PKNOX2 silencing or increased cellular sensitivity to DEB may be the cause of PKNOX2 silencing. It is also possible that FANCA exon 1-2 is required for PKNOX2 expression, which should be tested by further functional assays.

From many (n = 1639) transcription factors found in humans [46], we focused on HOX and TALE transcription factors that are strictly under epigenetic control during adult life. TGF-β signaling interacts with HOX genes [20-23], and we previously showed fluctuation of TGF-
β1 secretion from FA BM-MSCs [25]. Deregulated TGF-β signaling may disturb PKNOX2 expression in FA BM-MSCs and trigger disease progression, as seen in FA HSCs [19]. Dose- and time-dependent effects of TGF-β1 on cell cultures are well known [47, 48]. We performed the preliminary experiment by stimulating BM-MSCs from a donor with 0.1 or 5 ng/mL rTGF-β1 protein for 24, 48 or 72 hours (Online Resource 3). Following 24 hours of incubation, TGF-β1 expression increased linearly in a dose-dependent manner (Online Resource 3), thus further experiments were only performed on this time-point. Additionally, 5 ng/mL rTGF-β1 protein was the maximum induction dose used, because higher concentrations stimulate chondrogenic differentiation [48]. Wu and co-authors (2014) also show that increase in TGFβ-1 concentration increases senescence activity of BM-MSCs [47]. PKNOX2 expression of both FA and donor BM-MSCs were increased by rTGF-β1 in a similar dose-dependent manner, suggesting TGF-β1 signaling may not be perturbed in FA BM-MSCs. Our data confirm the results of an expression microarray study deposited to GEO database (GSE46019) that shows an increase in PKNOX2 expression of BM-MSCs following TGF-β1 stimulation [49]. Also, Zhou and co-authors (2013) report that overexpressed Pknox2 decreases p-Smad1/5/8 levels in mice [44]. All in all, our data in conjunction with these studies suggest that PKNOX2 and TGF-β signaling pathway are associated with each other. Secondly, we interrogated whether change in rTGF-β1 level altered the expression of any other TALE factors. To answer this question, MEIS1, an oncogenic transcription factor, as well as its cofactor, PBX1, were chosen [7, 50]. Stimulation of BM-MSCs did not affect the mRNA level of these genes, thus the dose-dependent effect of rTGF-β1 treatment is possibly constrained to PKNOX2 expression. Moreover, this study displayed that rTGF-β1 treatment up-regulated TGF-β1 expression of BM-MSCs in a dose-dependent manner, confirming a positive feedback loop shown previously [51]. It was intriguing that the dose dependence of this loop was slightly disrupted in the BM-MSCs of FA patients. Although
mouse models of FA do not resemble the complete characteristics of patients [52], it will be important to investigate whether in-vitro effect of rTGF-β1 treatment on the gene expression of BM-MSCs could be correlated with in-vivo studies.

In conclusion, PKNOX2 expression was downregulated in FA patient BM-MSCs compared to controls. Our results suggest that fluctuation in TGF-β1 levels may change PKNOX2 expression. Being one of the important members of bone marrow microenvironment, MSCs with deregulated PKNOX2 expression may impair the function of niche and would contribute to hematopoietic defects seen in FA patients, which needs to be elucidated further with functional analysis.

Conflict of Interest: The authors declare that they have no conflict of interest.

Funding: This study was supported by The Scientific and Technological Research Council of Turkey (TUBITAK; project no: 110S021 in conjunction with EU COST Action BM0805 designated as ‘HOX and TALE transcription factors in Development and Disease’ and TUBITAK project no: 214Z033).
References


Figure Legends

Fig. 1 HOX and TALE gene expression was conserved between FA patient and donor BM-MSCs. a Heat-map illustration of gene expression of BM-MSCs from FA patients (n = 12) and donors (n = 16). Dendrograms showed clustering of genes or FA and donor samples. Red color indicates high expression, whereas green color indicates low gene expression. b HOX and TALE gene expression was highly correlated between FA patient (n = 12) and donor (n = 16) BM-MSCs. However, PKNOX2 and HOXC13 were differentially expressed between groups.

Fig. 2 Relative expression of (a) HOXA, (b) HOXB, (c) HOXC, (d) HOXD, as well as (e) TALE class genes were highly conserved between FA (n = 12) and donor (n = 16) BM-MSCs. However, PKNOX2 expression of FA BM-MSCs was significantly lower than donor cells. Data are shown as means ± standard deviation (SD). * depicted statistically significant difference (P < 0.05). f DEB treatment had no effect on PKNOX2 expression of FA (n = 6) and donor (n = 3) BM-MSCs. BM-MSCs from a patient (HUSCS-FA04) had no expression of PKNOX2 (ΔCt = -25) following DEB treatment.

Fig. 3 PKNOX2 protein level of BM-MSCs derived from FA patients (n = 7) and donors (n = 6) was not significantly different (P > 0.05). BM-MSCs expressed two different PKNOX2 isoforms (70 and 52 kDa). a Protein samples (45 μg per lane) were run on two different 10% SDS-PAGE gels and the pictures were taken at the same time (exposure time = 5 minutes). b Ratio of PKNOX2 isoforms normalized to β-ACTIN was calculated.

Fig. 4 Fold change in (a) PKNOX2, (b) TGF-β1, (c) MEIS1 and (d) PBX1 expression of FA (n = 5) and donor (n = 5) BM-MSCs induced with 0.1 or 5 ng/mL rTGF-β1 for 24 hours was determined. Increase in PKNOX2 expression was significant in both FA and donor BM-MSCs induced with 5 ng/mL rTGF-β1 protein compared to their corresponding controls (adjusted P < 0.05). TGF-β1 expression of the donor BM-MSCs induced with 5 ng/mL
recombinant protein was also significantly higher than uninduced donor cells (adjusted \( P < 0.05 \)), while the expression level in FA BM-MSCs fluctuated within individuals. * depicted statistically significant difference (\( P < 0.05 \))

Fig. 5 rTGF-\( \beta \)1 protein induction had no effect on PKNOX2 protein level of FA (\( n = 3 \)) and donor (\( n = 3 \)) BM-MSCs. a Protein samples (20 \( \mu \)g per lane) were run on two different 10% SDS-PAGE gels and the pictures were taken at the same time (exposure time = 5 minutes). b Ratio of PKNOX2 protein isoforms normalized to \( \beta \)-ACTIN were calculated. PKNOX2 protein level did not differ (\( P > 0.05 \)) between FA and donor BM-MSCs at any experimental condition. Besides, PKNOX2 protein level within either FA patients or donors groups remained unchanged (\( P > 0.05 \)) upon induction
Figure 3

A

HUSCS-FA09.a  HUSCS-FA02  HUSCS-FA01  HUSCS-FA06  HUSCS-D13  HUSCS-D08  HUSCS-D09

PKNOX2 (70 kDa)  PKNOX2 (52 kDa)

β-ACTIN (45 kDa)

B

Bands at 70kDa

Ratios (Net PKNOX2/Net β-ACTIN)

Donor  FA

Bands at 52kDa

Ratios (Net PKNOX2/Net β-ACTIN)

Donor  FA
Figure 5

A

<table>
<thead>
<tr>
<th>HUSCS-FA09.a</th>
<th>HUSCS-D09</th>
<th>HUSCS-D14</th>
<th>HUSCS-FA03</th>
<th>HUSCS-FA01</th>
<th>HUSCS-D08</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 ng/ml rTGF-β1</td>
<td>0.1 ng/ml rTGF-β1</td>
<td>Control</td>
<td>5 ng/ml rTGF-β1</td>
<td>0.1 ng/ml rTGF-β1</td>
<td>Control</td>
</tr>
<tr>
<td>5 ng/ml rTGF-β1</td>
<td>0.1 ng/ml rTGF-β1</td>
<td>Control</td>
<td>5 ng/ml rTGF-β1</td>
<td>0.1 ng/ml rTGF-β1</td>
<td>Control</td>
</tr>
</tbody>
</table>

PKNOX2 (70 kDa)
PKNOX2 (52 kDa)

β-ACTIN (45 kDa)

B

<table>
<thead>
<tr>
<th>Bands at 70kDa</th>
<th>Bands at 52kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Net PKNOX2/Net β-ACTIN)</td>
<td>(Net PKNOX2/Net β-ACTIN)</td>
</tr>
</tbody>
</table>

- Control
- 0.1 ng/ml rTGF-β1
- 5 ng/ml rTGF-β1

Donor | FA

Ratio
0.0 | 1.0 | 2.0 | 3.0 | 4.0

Ratio
0.0 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0